




**Figure S1** Identification of the association between CALD1 and TMB and MSI. (A) The CALD1 mRNA expression was correlated with TMB in GBM + LGG, LGG, LAML, kidney cancer, THYM, OV, LUAD, STES, STAD, PRAD, HNSC, LIHC, THCA and UVM. (B) The CALD1 mRNA expression was correlated with MSI in MESO, TGCT, ACC, GBM + LGG, LUAD, ESCA, STES, kidney cancer, STAD, PRAD, HNSC and DLBC. (C) The mRNA expression of CALD1 was correlated with mDNasi in GBM + LGG, LGG, kidney cancer, THYM, THCA, MESO, SKCM, LUAD, COAD, COADREAD, ESCA, STES, SARC, KIRP, STAD, UCEC, HNSC, LUSC, TGCT, PCPG, and BLCA. (D) The expression of CALD1 was correlated with mRNasi in pan-cancer.



**Figure S2** The K-M survival and ROC curve of CALD1 in glioma. The K-M survival curve of CALD1 with OS (A), PFI (B), and DSS (C) in GBM. The K-M survival curve and ROC curve of OS (D), PFI (E), and DSS (F) in LGG. The data in parentheses are presented as 95% confidence intervals.



**Figure S3** Effect of CALD1 expression on the microenvironment of glioma. The correlation of CALD1 with ImmuneScore (A), StromalScore (B), and ESTIMATEscore (C).



**Figure S4** Western blot of CALD1 (A) and GAPDH (B) in different glioma cell lines.